BioSpace News Archive

Allied Corp. (“Allied”) (OTCQB: ALID), an international medical cannabis company focused on creating and providing targeted cannabinoid health solutions to address today’s medical issues, is pleased to announce the filing of a new United States provisional patent application entitled “Compositions and Methods for Modulating Endocannabinoid Systems Activity and Treating Mental Health Disorders”.

Turning Point Therapeutics, Inc. (NASDAQ: TPTX), a precision oncology company developing next-generation therapies that target genetic drivers of cancer, today announced the formation of a scientific advisory board to help guide the company’s early stage research and development of novel targeted therapies.

Genesis MedTech International has completed the acquisition of the Chocolate Touch ® drug-coated balloon (DCB), a drug-device technology asset from TriReme Medical LLC, a wholly-owned subsidiary of Singapore-listed QT Vascular Ltd, which engages in the design, assembly, and distribution of advanced therapeutic solutions for the minimally invasive treatment of complex vascular diseases.

SmartExam, Bright.md’s automated telehealth platform, will become an integral part of OHSU’s Virtual Care Hub in early October.

Walgreens Boots Alliance, Inc. announced the appointment of John Standley as President of Walgreens, effective immediately.

ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD) today announced the appointment of Dr. Gudarz Davar as Executive Vice President and Head of Research and Development. Dr. Davar will be responsible for leading research and development activities at ACADIA and will serve as a member of the company’s Executive Management Committee. In this role, he will report to Serge Stankovic, M.D., M.S.P.H., President of ACADIA. Dr. Stankovic will

Lineage Cell Therapeutics, Inc. (NYSE American and TASE: LCTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it received $24.6 million in cash from Juvenescence Ltd. , representing principal and interest due under a convertible promissory note. The note wa

Capricor Therapeutics today announced that it will be presenting at the LD 500 investor conference on Friday, September 4 at 9:20 AM ET / 6:20 AM PT. Linda Marbán, Ph.D, Chief Executive Officer, will be presenting to a live virtual audience.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company, today announces the appointment of Stefanie Johns, Ph.D., to the position of Chief Scientific Officer, effective September 2020 . In her role, Dr. Johns will further advance Hoth’s pipeline through both preclinical and clinical stages.

BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) today announced that the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health, has awarded BioCryst a new contract (75N93020C00055) totaling $44 million, and has added approximately $3 million to its existing contract (HHSN272201300017C), to support the development of galidesivir. The additional funds under these performance-base